Why the study?
Does reducing the furosemide dose to one-third of the stabilization dose maintain clinical and haemodynamic stability in patients with advanced congestive heart failure?
Does reducing the furosemide dose to one-third of the stabilization dose maintain clinical and haemodynamic stability in patients with advanced congestive heart failure?
In patients with advanced heart failure stabilized on medical therapy, reducing the furosemide dose by two-thirds is safe and well-tolerated in the majority of patients, with clinical deterioration being fully reversible upon dose resumption.
Answers are grounded in this paper and cite their sources.
May support short-term stability after furosemide reduction in advanced HF; leaves open randomized confirmation before practice change.
OBJECTIVES: This study was performed to examine the safety of reducing the long-term doses of furosemide administered to patients with congestive heart failure (CHF) stabilized on a standard medical treatment. METHODS AND RESULTS: Twenty-nine patients with advanced CHF were treated with enalapril, digoxin, nitrates, and furosemide, as needed to alleviate their symptoms, and remained clinically stable for at least 3 months on those doses. Subsequently, the daily dose of furosemide was reduced to 1/3 of the previous dose, while the concomitant therapy was unchanged. All patients underwent a thorough clinical evaluation and right-heart catheterization before and 2 months after the furosemide dose reduction. After the treatment optimization the NYHA functional class decreased from 2.3 +/- 0.6 to 1.4 +/- 0.6 (p = 0.000), and the left ventricular ejection fraction increased from 22 +/- 10% to 32 +/- 13%, (p = 0.000). Clinical and haemodynamic evaluation before and after 2 months of treatment with lower furosemide doses showed that 24 of the 29 patients (83%) remained in a stable NYHA functional class and maintained a stable haemodynamic status. In the remaining 5 patients (17%), mean NYHA functional class increased from 1.8 +/- 0.4 to 2.4 +/- 0.6 (p = 0.07), accompanied by a significant increase of the right and left ventricular filling pressures from 4.2 +/- 2.7 to 9.0 +/- 3.0 mm Hg, p = 0.018 and from 8.6 +/- 3.0 to 19.8 +/- 3.6 mm Hg, p = 0.017, respectively. These 5 patients returned to a stable clinical status upon resumption of the prior doses of furosemide. CONCLUSIONS: Most patients with chronic CHF who were clinically stabilized on high doses of furosemide remained stable on a maintenance dose equal to one-third of the dose needed for their stabilization. Patients unable to tolerate the dose reduction regained their previous clinical status following the resumption of the prior diuretic doses.
No takes yet. Share an insight, caveat, or question.
Alexopoulos et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: